Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.

Phase 3CompletedNCT00225524

Wyeth is now a wholly owned subsidiary of Pfizer150 enrolled

Overview

Phase III long-term safety study of Effexor XR in patients with major depression.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

150

Conditions

Depression

Interventions

Effexor XRDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816) Exclusion Criteria: * Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder

Locations (73)

Outcomes

Primary Outcomes

Incidence of adverse events

Secondary Outcomes

Quantitative data for laboratory data

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Nagoya, Aichi-ken, Japan

Unnamed facility

Nagoya, Aichi-ken, Japan

Unnamed facility

Ichikawa, Chiba, Japan

Unnamed facility

Ichikawa, Chiba, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Kasuga, Fukuoka, Japan

Unnamed facility

Kitakyushu, Fukuoka, Japan

...and 63 more locations